Behavioral Neuroscience – News and Features

In this interview, Dr. Eitan Schechtman explains how his lab is addressing some of the common misconceptions about sleep and the questions that keep even a sleep expert awake at night.

A new collaborative trial is exploring how music and VR could provide a personalized anxiety treatment. Technology Networks spoke with the team behind the trial to learn more.

High demand and supply shortages of weight loss drugs have presented opportunities for counterfeit drugs to enter the market. So, what are the dangers of counterfeits? And what can consumers look out for?

AI tools are revolutionizing neuroscience, enabling researchers to predict study outcomes with 86% accuracy and uncover novel connections across brain studies. This approach enhances hypothesis generation and optimizes resource allocation.

Adults who have been diagnosed with attention deficit hyperactivity disorder (ADHD) may be living shorter lives than they should, finds a world-first study led by UCL researchers.

APOBEC enzymes, which normally help fight viral infections by mutating viral DNA, cause repeat expansions and are unusually active in the brains of Huntington’s patients.

A study by Université de Montréal explores using virtual reality and hypnosis to ease pain and emotional distress in blood cancer patients. Personalized VR experiences transport patients to soothing environments.

A University of Arizona study reveals that PTSD and anxiety significantly reduce anti-Müllerian hormone levels, a fertility marker, in women firefighters. The findings highlight the impact of mental health on reproductive health.

Karolinska Institutet researchers identified dopamine-acetylcholine disruptions in the basal ganglia as key contributors to autism-related behavioral inflexibility. The study reveals how mutations in the eIF4E gene impair neurotransmitter release.

An analysis by researchers at the Brown University School of Public Health found that most studies exclude participants who are pregnant, potentially leaving critical safety and efficacy questions unanswered.